The effect of roxadustat combined with recombinant human erythropoietin on the curative effect, micro-inflammatory state and iron metabolism in patients with chronic renal failure complicated with renal anemia
10.3760/cma.j.cn115455-20230616-00664
- VernacularTitle:罗沙司他联合重组人促红素治疗慢性肾衰竭合并肾性贫血的临床研究
- Author:
Yilang WANG
1
;
Hongxia WANG
;
Xiufang FENG
Author Information
1. 义乌復元医院肾内科，义乌 322000
- Keywords:
Renal insufficiency;
Anemia;
Roxadustat;
Recombinant human erythropoietin;
Treatment outcome
- From:
Chinese Journal of Postgraduates of Medicine
2024;47(12):1104-1107
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the clinical efficacy of roxadustat capsule combined with recombinant human erythropoietin (rhEPO) in the treatment of chronic kidney failure (CKD).Methods:A total of 105 patients with CKD complicated with renal anemia who received treatment in Yiwu Fuyuan Hospital from October 2019 to October 2022 were prospectively selected and divided into observation group (53 cases) and control group (52 cases) according to random number table method. Both groups received maintenance hemodialysis treatment, while the control group received rhEPO intravenous injection treatment. On the basis of the control group, the observation group received roxadustat oral treatment. After 8 weeks of continuous treatment, the clinical efficacy of both groups was determined, and the anemia indicators, micro inflammatory factors and iron metabolism indicators were compared.Results:The total effective rate in the observation group was higher than that in the control group: 96.23%(51/53) vs. 80.77% (42/52), there was statistical difference ( χ2 = 4.46, P<0.05). After treatment, the levels of hemoglobin (Hb), red blood cell (RBC) and hematocrit (Hct) in the observation group were higher than those in the control group: (102.54 ± 9.37) g/L vs. (91.82 ± 10.20) g/L, (3.62 ± 0.59) × 10 12/L vs. (2.77 ± 0.63) × 10 12/L, 0.369 ± 0.068 vs. 0.288 ± 0.056, there were statistical differences ( P<0.05). After treatment, the levels of tumor necrosis factor-α, C-reactive protein and interleukin-6 in the observation group were lower those in the control group: (2.14 ± 0.56) μg/L vs. (3.26 ± 0.72) μg/L, (8.17 ± 2.44) mg/L vs. (10.73 ± 3.05) mg/L, (101.27 ± 14.95) μg/L vs. (123.74 ± 18.38) μg/L, there were statistical differences ( P<0.05). After treatment, The levels of ferritin, transferrin, transferrin saturation in the observation group were higher than those in the control group and hemodulin was lower than that in the control group: (288.47 ± 26.65) μg/L vs.(259.66 ± 24.80) μg/L, (2.81 ± 0.31) g/L vs. (2.43 ± 0.35) g/L, 0.351 ± 0.051 vs. 0.299 ± 0.053, (95.17 ± 17.56) μg/L vs. (106.49 ± 19.28) μg/L, there were statistical differences ( P<0.05). Conclusions:Roxadustat combined with rhEPO has a significant therapeutic effect on CKD complicated with renal anemia, which can effectively improve the patient′s micro inflammatory state and iron metabolism, alleviate anemia symptoms.
